Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Xenon Pharmaceuticals (XENE) PT Raised to $8 at Jefferies Following New Epilepsy Asset
May 10, 2017 10:35 AM EDTJefferies raised its price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $8.00 (from $7.00) while maintaining a Buy rating. The company added a new epilepsy asset, XEN1101, to their portfolio.
TV-45070 topline results are expected mid-2017. An IND for '901 is planned for 4Q17, and... More



